Physician profile
Raman Verma
NPI 1558368928
$3,025.10
in general payments reported to CMS, 2019-2025
32 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $784 · 2020: $868 · 2021: $645 · 2022: $443 · 2023: $285.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $285.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $284.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $545.62 | 2019-2023 | Trelegy Ellipta |
| Amgen INC. | $423.43 | 2019-2022 | |
| Lilly USA, LLC | $321.30 | 2019-2023 | Mounjaro |
| Boehringer Ingelheim Pharmaceuticals, INC. | $153.63 | 2019-2022 | |
| Pfizer INC. | $137.65 | 2019-2021 | |
| Amarin Pharma, INC. | $131.18 | 2019-2021 | |
| Vifor Pharma, INC. | $125.00 | 2019 | |
| Merck Sharp & Dohme LLC | $119.94 | 2019-2020 | |
| Ironwood Pharmaceuticals, INC | $96.40 | 2019 | |
| Axsome Therapeutics, INC. | $93.80 | 2023 | Auvelity |
| E.R. Squibb & Sons, L.L.C. | $87.32 | 2019-2021 | |
| Sunovion Pharmaceuticals INC. | $84.93 | 2019-2021 | |
| Mylan Specialty L.P. | $75.78 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $67.47 | 2020-2021 | |
| Sanofi-Aventis U.S. LLC | $66.71 | 2020-2023 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $53.71 | 2020 | |
| Biohaven Pharmaceuticals, INC. | $47.41 | 2021 | |
| Sumitomo Pharma America, INC. | $43.76 | 2023 | Gemtesa |
| Medtronic Vascular, INC. | $42.61 | 2020 | |
| Abbvie INC. | $37.75 | 2020-2021 | |
| Allergan, INC. | $37.03 | 2020 | |
| Mannkind Corporation | $32.73 | 2019 | |
| Medtronic, INC. | $30.13 | 2022 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $24.99 | 2022 | |
| Corcept Therapeutics | $24.30 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $20.35 | 2019 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $19.35 | 2022 | |
| Esperion Therapeutics, INC. | $18.57 | 2020 | |
| Dexcom, INC. | $16.58 | 2023 | Dexcom G6 Transmitter |
| Astrazeneca Pharmaceuticals Lp | $16.50 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $16.47 | 2021 | |
| Janssen Pharmaceuticals, INC | $12.70 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Raman Verma listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.